All In Biotech

Drug Trial Radar · NCT06255951

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

This is a Single-center, Two-sequence, Open-label, Two-cycle Drug-drug Interaction (DDI) Study in Healthy Subjects. To Evaluate the Effects of Itraconazole Capsules, a Strong Inhibitor of CYP3A4, and Rifampicin Capsules, a Strong Inducer, on the Pharmacokinetics of TY-9591 Tablets After a Single Oral Dose

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Mar 12, 2024

Primary completion

May 23, 2024

Study completion Dec 27, 2024

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Feb 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Studies evaluating the effects of itraconazole or rifampicin on the pharmacokinetics of TY-9591 tablets in healthy subjects

Conditions

  • NSCLC

Interventions

  • ItraconazoleDrug

    The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartA was the itraconazole study sequence, which was used to study the effect of itraconazole on the pharmacokinetic characteristics of TY-9591 tablets after multiple doses.

  • RifampicinDrug

    The study was divided into two sequences with a planned enrollment of 48 healthy adult subjects (24 in each sequence). PartB was the rifampin study sequence, which investigated the effect of multiple doses of rifampin on the pharmacokinetic profile of TY-9591 tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Peak plasma concentrations (Cmax) of TY-9591 and its metabolites D1 and D2Time frame: through study completion,an average of 6 months
  2. Area under the concentration-time curve from 0 to the last quantifiable time point after dose administration (AUC0-t)Time frame: through study completion,an average of 6 months
  3. Area under the concentration-time curve from 0 to infinity (AUC0-inf), as data permitTime frame: through study completion,an average of 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yali Liu

    Guangdong, Shantou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.